110 related articles for article (PubMed ID: 10376982)
1. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.
Walls J; Assiri A; Howell A; Rogers E; Ratcliffe WA; Eastell R; Bundred NJ
Br J Cancer; 1999 Jun; 80(8):1265-70. PubMed ID: 10376982
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of deoxypyridinoline in patients with breast cancer.
Nguyen-Pamart M; Bonneterre J; Hecquet B
Anticancer Res; 1995; 15(4):1601-3. PubMed ID: 7654055
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring markers of bone turnover in multiple myeloma].
Spicka I; Spacek P; Hulejová H; Procházka B; Cieslar P; Chrz M; Válková V; Klener P
Vnitr Lek; 1999 Aug; 45(8):463-7. PubMed ID: 11045145
[TBL] [Abstract][Full Text] [Related]
5. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
[TBL] [Abstract][Full Text] [Related]
6. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
7. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
Takeuchi S; Saitoh H
Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
[TBL] [Abstract][Full Text] [Related]
8. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.
Hou MF; Lin SB; Yuan SS; Tsai LY; Tsai SM; Hsieh JS; Huang TJ
Ann Clin Lab Sci; 2003; 33(1):55-61. PubMed ID: 12661898
[TBL] [Abstract][Full Text] [Related]
11. Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease.
Topkan E; Karaoglu A
J Exp Clin Cancer Res; 2007 Dec; 26(4):553-9. PubMed ID: 18365552
[TBL] [Abstract][Full Text] [Related]
12. Abnormal formation of collagen cross-links in skin fibroblasts cultured from patients with Ehlers-Danlos syndrome type VI.
Pasquali M; Still MJ; Vales T; Rosen RI; Evinger JD; Dembure PP; Longo N; Elsas LJ
Proc Assoc Am Physicians; 1997 Jan; 109(1):33-41. PubMed ID: 9010914
[TBL] [Abstract][Full Text] [Related]
13. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer.
Lüftner D; Richter A; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):1017-26. PubMed ID: 12820341
[TBL] [Abstract][Full Text] [Related]
14. Can bone markers guide more effective treatment of bone metastases from breast cancer?
Clemons M; Cole DE; Gainford MC
Breast Cancer Res Treat; 2006 May; 97(1):81-90. PubMed ID: 16319976
[TBL] [Abstract][Full Text] [Related]
15. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
16. Markers of bone turnover in prostate cancer.
Garnero P
Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
[TBL] [Abstract][Full Text] [Related]
17. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
19. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
Cheung KL; Robertson FR
Minerva Chir; 2003 Jun; 58(3):297-303. PubMed ID: 12955047
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
Takahashi S
Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
